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Summary.-Between 1977 and November 1979 we have treated 53 patients with
malignant teratomas (43 males, 10 females). Thirty (700o) out of the 43 male patients
had advanced and bulky disease at the time of presentation. Using different drug
combinations in a sequential manner as described below, results are as follows: of
the initial 33 male patients, 22 (67O ) have discontinued treatment (mean 9-5 months).
Nineteen have responded completely and 3 have static computed tomography (CT)
nodules. Life-table analysis projects a survival of66% (analysis at 1 December 1979).
Nine out of 10 ovarian teratoma patients are alive. Adverse prognostic factors at the
start of treatment were recognized in 9/10 male patients and the 1 female patient who
have died. Although the survival of patients with malignant teratomas has improved
dramatically, there are still problems with drug resistance in patients with very
advanced disease. Patients with these tumours should continue to be treated in
centres specializing in managing what has now become a potentially curable disease
in most cases.
IT HAS LONG been recognized that
metastatic malignant teratomas can re-
spond dramatically at first to single-agent
and combination chemotherapy. In 1960
Li et al. reported 3/23 complete remissions
with a drug combination ofactinomycin D,
methotrexate and chlorambucil. In 1972
Smithers collected reports of 65 cases of
documented complete remissions with
malignant teratomas, but only 25 of these
lasted more than 2 years and I 1 more than
5 years. In 1975 and 1976 Samuels et al.
reported the use of high-dose vinblastine
and bleomycin infusions, and obtained 22/
70 (31 Oo) complete remissions. The intro-
duction of cis-platinum in combination
with vinblastine and bleomycin has fur-
ther improved the rate of complete
remission. In 1977 Einhorn & Donohue
reported that 32 out of 50 patients (64%)
achieved complete remissions. A more
recent analysis (Einhorn & Williams, 1979)
shows that 28 (56%) of these patients are
still in complete remission, with a mini-
mum follow-up time of 28 months. A
further report of 40 patients using this
drug combination by Stoter et al. (1979)
obtained 24 (600o) complete remissions
with 22 remaining tumour-free for 5-30
months. Samson et al. (1979) also using
cis-platinum, vinblastine and bleomycin
obtained a complete remission rate of 64/
126 patients (51%).
Two further aspects of malignant tera-
tomasthat arenowrecognizedasimportant
in their management are the recognition
of tumour bulk and the use of the tumour
markers, human chorionic gonadotrophin
(hCG) and alpha-foetoprotein (AFP). We
have used the Royal Marsden Hospital's
staging classification (Peckham et al.,
1979). Most malignant teratomas produce
hCG or AFP or both (Lange et al., 1976;
Newlands et al., 1976; Scardino et al.,
1977). When these markers are at raised
levels they provide the most rapid and
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sensitive means of monitoring therapy andl
detecting new agent activity in malignant
teratomas (Newlands, 1978; Javadpour,
1 979; Barzell & Whitmore, 1 979).
1PATIENTS ANI) METHODS
43 mi-ale patienits w-ith malignant teratomica
(aged 16-64 years, mean 28) have been
treated between 1977 and 1979. There w%ere
38 testicular primaries, 2 inediastinal pri-
mlaries and 3 patients uwith para-aortic
disease but no identified pritnary in the testis.
Staying
The staging classification describes tumiiour
extent. site(s). and volume (Pecklham et al..
1979):
1. Disease limited to testis. No evidenice of
metastases.
II. Para-aortic node spread.
A-metastases < 2 cm diaImeter
B metastases 2-5 cm diameter
C mnetastases > 5 cm diameter.
III. Supradiaphragmatic lymph-node in-
volvement.
Abdorninal status A, B and C, as above.
I-V. Extralymphatic metastases.
LI-up to 3 metastases < 2 cm diameter
1J2- > 3 metastases < 2 cm diameter
L3-metastases >2 cm diameter
H+=liver involvement.
The clinical stages ofthemale patients were:
1: 1; It: 4; f11: 4; IV: 34. Thirty (70 0) out of
43 male patients had advanced and bulky
disease by this classification, i.e. had deposits
> 5 cm in diameter, L3, H-t or combination,
of these sites of involvement.
The incidence of the tumour markers
human chorionic gonadotrophin (hCG) and
alpha-foetoprotein (AFP) in the male patients
were as follo'ws: hCG alone, 8; AFP alone, 9:
both hCG and AFP, 24; no markers. 2.
Histology of the male patients was: malig-
miant teratoma intermediate (MTI) 12 (28%);
rnalignant teratoma undifferentiated (MTU)
23 (53%0); maliginant teratoma trophoblastic
(MTT) 8 (19%). Ten of these tumours also
contained a seminomatous element.
Ten patients with malignant ovarian
teratomas (aged 5-31 years. mean 18) have
also been treated. For comparison the male
staging svstem was used. The clinical stages in
theise patients were: II: 3: IV: 3; tuimouIr
marker(s) only: 4. The incidence of the
tumour markers were: hCG alone, 2: AFP
alone, 4: hCG and AFP, 3; no markers. 1.
Treatineidt
Patients wvho -were referred with clear-cut
diug resistance to some of the drugs in the
protocol were excluded from this study. The
chemotherapy schedules, which were partly
b)ased on previous reports (Newlands. 1978:
Higby et al., 1974; Hayes et al., 1977; New-
lands & Bagshawe, 1977; Ne-wlands, 1976b)
w\ere:
Treatnent A.-Day 1: vincristine 1 mg/M2
i.v. 10:00; methotrexate 100 mg/m2 iv. start
15:00, followed by methotrexate 200 mg/Mi2
as a 12h infusion. Day 2: bleomycin 15 mg
given as a 24h infusion. Folinic acid rescue
started at 15:00 in a dose of 15 ing 12-hourly
for 4 doses. Day 3: bleomycin infusion 15 mg
by 24h infusion. Day 4: forced diuresis -with
mnannitol and hydration at the rate of 1 I/h
was given for 3 h prior to cis-platinum 120
mg/mn2 bv a short iv. infusion, and the
diuresis wias continued at 1 1/h for a further
3 h with mannitol. Hydration was continued
until the patient stopped vomiting.
Treatment B.-VP.16-213 (Etoposide) 100
ng/m2 i.v. Days 1-5; actinomycin-D (S5 mg
i.v. Days 3. 4 and 5; cyclophosphamide 500
mg/m2 i.v. Day 5.
Treatment C.-Hydroxyurea 500 mg q.d.s.,
p.o., Days 1 and 2; vinblastine 5 mg/M2 i.v.
Day 3; chloriambucil 10 mg b.d.. p.o., Days;
3, 4 a,nd 5.
Treatment D. Day 1: vincristine 1)0 img/
i112 i.v. at 10:00; methotrexate 100mg/Mi2 i.v.
start at 15:00, followed by methotrexate 200
nmg/n2 i.v. as a 12h infusion. Day 2: bleo-
Inycin 15 iIlg by 24h infusion. Folinic acid
rescue started at 15:00 in a dose of 15 mg
12-hourly for 4 doses. Day 3: bleomycin
15 mg by a 24h infusion.
flhe schedule of treatments was: A, A, B.
C, D. B. The courses were continued in the
sequence B. C and D. unless there was
evidence of drug resistance. When this
occurred. the inappropriate treatment wa,s
omitted. (See note added in proof.)
Responses
A conmplete response required complete dis-
appearance of clinical, biochemical and CT
scanning evidence ofdisease. or necrotic tissue
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on removal or biopsy of any residual lesions
where these were present.
Partial responses with >50% reduction in
measurable lesions were divided into: (1) par-
tial response with unresectable differentiated
teratoma and negative tumour markers,
referred to as PRD, (2) partial response with
static residual nodules on CT scanning and
negative tumour markers, referred to as
PRCT, and (3) partial response with evidence
of disease activity, referred to as PRA. No
further maintenance therapy was given once
a complete response, PRD or PRCT had
lasted for 3 to 4 months.
Radioiimmunoassay
HCG and AFP were measured by a specific
radioimmunoassay according to methods pre-
viously described (Kardana & Bagshawe,
1976).
RESULTS
The results in 33 male patients (ex-
cluding the 10 patients who are responding
and still on treatment) show that 22 (67%)
of the initial 33 patients have been off
treatment for periods of 1-20 months
(mean 9.5). There have been 19 (570)
complete responses; 1 (3%O) PRD; 2 (6%)
PRCT. Only 1 (3%) patient has drug-
resistant disease and PRA. So far only
1 patient who had a complete response has
relapsed and is responding to treatment.
Fig. 1 shows a life-table analysis of all 43
patients, which projects a survival of
66%. Fig. 2 illustrates the use of tumour
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FIG. 1. Survival of male patients withi
malignant teratoma. Life table of 43
patients to 1.12.79.
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FIG. 2. Tumour-marker response in a
patient with undifferentiated Stage IV
malignant teratoma. The chemotherapy
abbreviations are as follows: VCR, vin-
cristine; MTX, methotrexate; BLEO, bleo-
mycin; PLATINUM, cis-platinum; VP16,
VP.16-213 (etoposide); AD, actinomycin-
D; CYCLO, cyclophosphamide; HU,
hydroxyurea; VBL, vinblastine; CHLOR,
chlorambucil.
markers hCG and AFP to monitor a
response to chemotherapy.
Analysis of the results in relation to the
initial bulk of tumour at presentation is
given in Table I. There has been 1 (70o)
death in 13 patients with non-bulky
disease. Nine (30%) of 30 patients with
bulky disease have died. There were 6
deaths from resistant malignant teratoma
after an initial response. The primary
histology in these patients was: MTU, 5;
MTT, 1. The other causes of death were:
initial extent of disease, 1; massive
pulmonary embolus in a patient respond-
ing to treatment, 1; septicaemia due to
neutropenia, 1; pulmonary oedema while
off treatment, 1. The patient who died
from septicaemia had massive abdominal
TABLE I.-Analysis of 43 male malignant
teratoma patients by tumour bulk and
stage
Bulk staging
<2 cm+Ll+L2
2-5 cm
>5 cm+L3
Total
Clinical stage
A
I II III IV
_ 1 (1) 9
- 2 1 -
1 2 2 (2) 25 (7)
1 4 4 (3) 34 (7)
Total
10 (1)*
3
30 (9)
* In parentheses number dead.
O!
380CHEMOTHERAPY OF ADVANCED MALIGNANT TERATOMAS
disease with obstruction of the duodenum.
Despite rapid response in the tumour, his
nutritional state was poor and contributed
to the profound myelosuppression. The
patient who died of pulmonary oedema
was a man of 56, with a history of cardiac
disease, who had received a course of cis-
platinum in reduced dose without intense
hydration one week before the pulmonary
oedema.
When analysed by disease site, there
were 3 deaths in 8 patients with advanced
pulmonary disease (L3) and non-bulky
abdominal disease (A, B). Two out of 5
patients with advanced abdominal disease
(C) and early pulmonary disease (LI, L2)
have died. Four out of 8 patients with
advanced abdominal (C) and advanced
lung disease (L3) have died. At present all
4 patients with hepatic metastases (H+)
are alive, and 2 are off treatment.
The tumour markers hCG and AFP are
not only useful in monitoring therapy,
they also have prognostic value for the
outcome of therapy. Analysis of our pre-
vious series of male teratomas shows that
when the hCG > 105 miu/ml and the AFP
> 103 MRC u/ml there was a very poor
prognosis (Germa-Lluch, Begent, Bag-
shawe, unpublished observations). The
trend in the current group of male
patients supports the use ofthese markers
in identifying high-risk patients (Table II).
A number of patients had residual CT-
scan abnormalities at the end of treat-
TABLE 11.-Analysis of 43 male patients
with malignant teratoma by tumour
marker concentrations (miu/ml for hCG,
MRC u/ml ofAFP)
Highest tumour marker
{hCG <5x 104
AFP <5x 102
{hCG 5x104-1x 105
AFP 5x 102-1 x 103
hCG > 1x 105+AFP>1 x 103
No. of
patients 0
(dead) Dead
22(2) 9
9 (3)
12 (5)
33
42
ment, or evidence of disease activity, and
underwent surgery. Results are as follows:
3 patients had only necrotic tissue and 6
had histology showing more differentiation
of the teratoma than the original primary,
and all 9 are alive. There were 7 patients
with active teratoma on repeat histology,
and only 2 of these are alive.
The toxicity encountered with this
chemotherapy is relatively mild, and less
than our previous experience with regi-
mens including high-dose vinblastine.
Haematological toxicity is summarized in
Table III. Febrile episodes associated with
neutropenia and given antibiotic cover
occurred in 13 (24%) of 53 patients. All
patients experienced some nausea and
vomiting on high-dose cis-platinum. Some
patients had evidence of high-frequency
hearing loss on audiometry, but in none of
these was the hearing loss severe enough
to be socially noticeable. Renal impair-
ment was mild and the elevations in blood
TABLE III.-Side effects of chemotherapy in relation to previous treatmient. 43 teratomas
in males and 10 ovarian teratomas
Previous treatment
No. of
patients
(0)
Total 53
Side effects (at any time
during treatment)
Leucopenia* 41 (77)
Thrombocytopeniat 10 (19)
Raised creatininet 19 (36)
Complications
Leucopenia with fever
(receiving antibiotics) 13 (24)
* <2000x109/l.
None (%)
39
29 (74)
5 (13)
11 (28)
Radiotherapy
(%)
11
10 (91)
4 (36)
8 (73)
8 (20) 4 (36)
t <50,000x109/1. t>120,ui.
Radiotherapy
and
chemotherapy
(%o)
3
2 (67)
1 (33)
0 (0)
1 (33)
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uirea and creatinine retture(ed towards
normal in patients stopping therapy.
Life-table analysis of the 10 patients
with malignant ovarian teratomas is
shlown in Fig. 3, and 9/10 of the patients
are alive, witlh I PRD andl I PRA.
I)1SCUSSM1N
'I'he aimn of chemotherapv in advanced
malignant teratomas is to achieve a
stable, complete remnission. The general
experienice is that partial remissions,
withouit histological evidlence of differen-
tiatioin ofthe teratomiia (Merrin et al., 1 975;
Hong et aW., 1977) atre of little benefit to
the p1atient ini termns of inicreased survival.
Before 1975), the results at (haring (ross
Hospital showed that 4 (70/,) ouit, of 58
patients wxAith advanced disease went into
prolonge(d remission. ''l'lis is a simnilar
experience to that ofPecklhamii et at. (1 977),
who reported 13 (120%,) otut of 105 Stage IV
teratomna patients remaining in remnission
before the aldvent of vinblastine aind bleo-
mn,ycin infuisions and(I the introduction of'
cis-platinulm. Since the growth rate of
most teratomas is very rapid, the majority
of relapses occtur' within the first 2 years of'
completing treatment (Einhorn & WVil-
liams, 1979; Peckhaml et al., 1977).
Although the follow-up of our series is
relativel, short, we hope that the strict
criteria for defining complete remission,
together withi histological confirmatrion of'
the natuire of any residtual no(ltiles or
mnasses, will mean that we will see few
relapses in this group. Writh the Irapi(l
improvemenit in therapy, wN-e think that
histological confirmiiation of' residuial
nmasses is important, since they may repre-
sent necrotic tissue, dlifferentiatecl terat-
oma oi active tumour. XVe (1o not give
routine raldiotheral)v to latients with
residuLal masses, since those writh necrotic
tissue or differentiated teratomna are doing
well without it. WVhere there is active
teratoma,that is tresistant tochemotherapy,
otur experience has beeni that the tumorll
lhas also beenl resistatnt to radiotherapy at
this stage.
The optimtuml duiration ofchemotherapy
in advanced malignant teratomas is as yet
unknown. It seems unlikely to us that
what may be a(lequate chemotherapy for
the patient with minimnal (lisease will be
adequate for a patient wvith gross builk of
tumour in multiple sites. In this study we
lhave taken a flexible approach to the total
(luration of treatment. WVe have aimed at
complete biochemical normality in the
h(CCG and(I AFP for 12 weeks, together
with the resolution of radiological an(l
clinical disease. At this stage the patients
have been CT scanned, acnd if there was
no eviidence of residual disease treatment
wvas stopped. If the CT scan was still posi-
tive the patient conitinued treatment for
a further 2 months, and wlas then re-
scanned. If residutal abnorrmalities were
found on repeat CT scanI, sturgical resection
or biopsy was performed. The (lutriation of
treatment (lepended oII howx, rapidly the
patient went into complete remnission, the
lange being 4-18 months (mean 7.8). It is
possible that a shorter treattment may be
adequate, btut in this studv ve lhave
emphasized the need for a complete re-
mission as the overridliing -aim. We have
given no niaintenance therapy, and so far-
this policy hals been justified by the
results.
The recognition of adverse prognostic
factors such as the initial bulk of tumour
masses, disease in particular sites such as
the central nervouis system, together with
very high levels of hCG', and AFP (Table Il
andl uinpublished observations) mneans that
patients who are going to be diffictult to
cuLre can be identified from the start of
treatmenit. Resuilts from several centres
(Samuels et al., 1975; Einhorni & Doniohue,
1977; Stoter et al., 1979; Peckham et al.,
1979; Cheng et al., 1978; Golbey et at.,
1 979) and ourselves inidicate that, the com-
plete remission rate is high in patients pre-
senting with small tumour burdens. How-
eveer, those with gross tuimour btulk at the
timne of starting treatment are the main
soUrIce of therapeutic failture and in
Einhorn's series (Einhorn & Donolhue,
1977; Einhorn & WNTilliams, 1979) about
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half the patients with bulky tumour have
died. We do not regard the platinum,
vinblastine, bleomycin regime (PVB) as
standard therapy for this type of patient.
In our view the main advantages of our
sequential pattern of chemotherapy over
PVB is that the major side effects are
associated only with the courses of cis-
platinum. The complications associated
with high-dose vinblastine (marked
neutropenia, myalgia, back-ache and con-
stipation) are avoided.
Prior radiotherapy does not appear to
be an adverse prognostic factor in this
series, though the haematological toxicity
with the chemotherapy was more pro-
nounced (Table III). In this group, the
patients with prior irradiation were fol-
lowed more closely, and presented with
less advanced disease than the others. In
patientswith differentiated teratoma when
the residual disease was resected, the
aggressive parts of the tumour were
closely associated with the trophoblastic
and yolk-sac elements of the teratoma,
producing hCG and AFP respectively. In
the 2 patients (1 male, 1 female) with un-
resectable differentiated teratomas, the
markers have been normal and the clinical
situation has been static, which agrees
with the favourable prognosis reported in
this situation (Merrin et al., 1975; Hong
et al., 1977). Sixteen patients in this study
have had surgery after bleomycin therapy,
and so far there has been no pulmonary
toxicity.
Malignant ovarian teratomas are rare,
but in our small series many of the thera-
peutic lessons learnt from male malignant
teratomas are clearly applicable. Nine of
the 10 patients had raised tumour markers
and these correlated closely with response
to therapy and clinical remissions. Pre-
vious reports (Curry et al., 1978; Cangir et
al., 1978; Slayton et al., 1978) of chemo-
therapy have mainly used vincristine,
actinomycin-D and cyclophosphamide
(VAC) and a number of complete re-
missions have been obtained. Survival in
these reports was related to the extent of
disease prior to chemotherapy. We have
10-
, 8
6-
* dead patients
isurviving patients off treatment
-surviving patients on treatment
5 10 1S 20
Months
25 30 35
FIG. 3.-Survival of female patients withi
malignant teratoma. Life table of 10
patients to 1.12.79.
treated our ovarian teratomas in the same
way as the male teratomas. More of these
patients had less advanced disease than
the male patients, and this probably con-
tributes to the good prognosis shown in
Fig. 3.
We have also treated a limited number
of other germ-cell tumours during this
period: 6 male teratomas which had per-
sisted after extensive previous chemo-
therapy at other centres (complete re-
mission, 2; resistant active disease, 1;
dead from malignant teratoma, 3). We
have also treated 3 advanced seminomas
(2 are in remission and 1 is dead) and 1
advanced dysgerminosa, who is in com-
plete remission.
The introduction ofcis-platinum in drug
combinations in the management of ad-
vanced malignant teratomas has produced
a dramatic improvement in the proportion
of patients achieving a complete re-
mission, and many of these will probably
be cured. With the number of chemio-
therapeutic agents active against malig-
nant teratomas, including VP.16-213
(Newlands, 1978; Newlands & Bagshawe,
1977; Fitzharris et al., 1980) we feel that
further improvements can be made in
therapy by finding the best combination
of these agents. We think that the
sequential chemotherapy results that we
have reported here are as good as any other
reported series, allowing for the high pro-
portion (70%) of the male patients pre-
senting with advanced and bulky disease.
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Note added in proof
Modification of treatment schedules since 1.12.79.
Since this analysis we have modified the treatment
sequences because several patients showed tumour
resistance to treatment C and there has been no
major toxicity from repeating treatment A more
than twice. The current sequence of treatment is:
A,A,B,A, B,D,B,D, etc.
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